This course has expired. You can still review the content but course credit is no longer available.
Introduction and Overview: Where We’ve Come in Gene Therapy by Allen Ho, MD
Ocular Gene Therapy Delivery by Robert Avery, MD
Gene Therapy for Wet AMD: Current Clinical Trials by Jeffrey Heier, MD
Changing Retinal Landscape and Implications for Future Therapies by Pravin Dugel, MD
Closing Comments and CME posttest by Allen Ho, MD
Supported by an educational grant from REGENXBIO Inc.
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians
Credit Designation Statement
Evolve Medical Education LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Allen C. Ho, MD, FACS
Professor of Ophthalmology
Thomas Jefferson University
Director of Retina Research
Wills Eye Hospital
Mid Atlantic Retina
Chief Medical Editor, Retina Today
Robert Avery, MD
California Retina Consultants
Santa Barbara, CA
Associate Medical Editor, Retina Today
Pravin U. Dugel, MD
Managing Partner, Retinal Consultants of Arizona
Clinical Associate Professor of Ophthalmology, Doheny Eye Institute, Keck School of Medicine, University of Southern California
Physician Executive Director, Banner Eye Institute
Founding Partner, Spectra Eye Institute
Sun City, AZ
Retina Today Editorial Board Member
Jeffrey S. Heier, MD
Co-President and Medical Director
Director of the Vitreoretinal Service
Director of Retina Research
Ophthalmic Consultants of Boston
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
Robert Avery, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera, Allergan, Amgen, Apellis, Bausch + Lomb, Clearside, Eyepoint, Genentech, Helio, lridex, Notal, Novartis, OcularTheraputix, Regeneron, Replenish, and Santen. Grant Research: Genentech. Shareholder: Alcon, Novartis, Regeneron, and Replenish.
Pravin U. Dugel, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/ Advisory Board Member: Abbott/AMO, Acucela, Aerie Pharmaceuticals, Aerpio, Alcon, Alimera Sciences, Allergan, Amgen, Annidis, ArticDX, Avalanche, Bausch + Lomb, Boehringer lngelheim, ByeOnics, Carl Zeiss Meditec, Chengdu Kanghong Biotechnology, Clearside Biomedical, CDR-Life, Inc., Digisight, Dose Medical, Genentech, Graybug Vision, lrenix, Kodiak Sciences, Lutronic, Lux Bioscience, Macusight, NeoVista, Neurotech, Novartis, Oculis, Ophthotech, Omeros, Opthea, Optovue, ORA, Orbis International, Panoptica, Pentavision, pSivida Corporation, QLT, Inc., Regeneron, Roche, Santen, SciFluor Life Sciences, Shire Human Genetics, Spark Therapeutics, Stealth Biotherapeutics, Thrombogenetics, Topcon, and TrueVision. Stock/Shareholder: Aerpio, Alimera, Annidis, ArctixDx, Clearside Biomedical, Digisight, lrenix, Ophthotech and PanOptica.
Jeffrey S. Heier, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: 4DMT, Aerie, Aerpio, AKROS, Alkahest, Apellis, Array, Asclepix, Bayer, Biomarin, Beaver Visitec lnt’I, Daiichi, Eloxx, Galecto, Galimedix, Genentech, Generation Bio, Helie, Interface, lrenixx, Janssen, Kala, Kanghong, Kodiak, Notalvision, Novartis, Omeicos, Orbit Bioemedical, Regeneron, RegenXBio, Retrotope, Scifluor, Shire, Stealth BioTherapeutics, Thrombogenics, Voyant, and Zeiss. Grant Research: Aerpio, Apellis, Clearside, Daiichi, Foreseehome, Genentech, Genzyme, Hemera, Janssen, Kalvista, Kanghong, Novartis, Ocudyne, Ophthotech, Optos, Optovue, Regeneron, RegenXBio, and Thrombogenics. Shareholder: Adverum,Aldeyra, Allegro, Digital Surgery Systems, Ocular Therapeutics, and Jcyte.
Allen C. Ho, MD, FACS, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerpio, Aerie, Alcon, Allergan, Asclepix, Beaver EndoOptiks, BioTime, Chengdu Kang Hong, Eloxx, Everads, Genentech, Janssen, Notal, Ocugenix, ONL, Optovue, Orbit Biomedical, PanOptica, PRN, ProQR, Regeneron, RegenxBio, Sanofi, and Second Sight. Grant Support: Aerie, AGTC, Alcon, Allergan, Apellis, Chengdu Kang Hong, Genentech, Janssen, NEI/NIH, ProQR, Regeneron, RegenxBio, Sanofi, and Second Sight. Ownership: Covalent, ONL, PanOptica, PRN, and Visionary Ventures.
Editorial Support Disclosures
Erin K. Fletcher, MIT, director of compliance and education; Susan Gallagher-Pecha, director of client services and project management; Cassandra Richards, director of education development, Evolve have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, or REGENEXBIO Inc.